• Explore /
  • Poster
  • / PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).

PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).

Abstract Poster

Authors

Andrea Necchi

Andrea Necchi

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Andrea Necchi , Luigi Mariani , Andrea Anichini , Antonella Messina , Patrizia Giannatempo , Daniele Raggi , Alberto Briganti , Francesco Montorsi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

2017-002379-24

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS534)

DOI

10.1200/JCO.2018.36.6_suppl.TPS534

Abstract #

TPS534

Poster Bd #

N12

Abstract Disclosures

Similar Posters

First Author: Andrea Necchi

First Author: Andrea Necchi

First Author: Robert A. Ramirez

First Author: Tony S. K. Mok